• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用扩散加权 MRI 无创表征原位形成植入物的扩散系数。

Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.

机构信息

Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Dr., West Lafayette, IN 47907, USA.

Basic Medical Sciences, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907, USA.

出版信息

J Control Release. 2019 Sep 10;309:289-301. doi: 10.1016/j.jconrel.2019.07.019. Epub 2019 Jul 16.

DOI:10.1016/j.jconrel.2019.07.019
PMID:31323243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6815723/
Abstract

In situ forming implants (ISFIs) form a solid drug-eluting depot, releasing drug for an extended period of time after a minimally-invasive injection. Clinical use of ISFIs has been limited because many factors affect drug release kinetics. The aim of this study was to use diffusion-weighted MRI (DWI) to noninvasively quantify spatial-temporal changes in implant diffusivity in situ. ISFIs were formed using poly(lactic-co-glycolic) acid, with a molecular weight of either 15 kDa or 52 kDa, and fluorescein as the mock drug. Drug release, polymer erosion, polymer degradation, and implant diffusivity were analyzed in vitro over 21 days. DWI was also performed in vivo over 5 days. Spatial diffusivity maps of the implant were generated using DWI data. Results showed constant diffusivity at the implant shell ((1.17 ± 0.13) × 10 mm/s) and increasing diffusivity within the interior over time (from (0.268 ± 0.081) × 10 mm/s during day 1 to (1.88 ± 0.04) × 10 mm/s at 14 d), which correlated with increasing porosity of the implant microstructure. Implants formed in vivo followed the same diffusivity trend as those in vitro. This study validates the use of DWI to provide novel functional information about implant behavior through its ability to noninvasively characterize transport properties within the implant both in vitro and in vivo.

摘要

原位形成植入物(ISFI)形成固体药物洗脱库,在微创注射后可延长药物释放时间。由于许多因素会影响药物释放动力学,因此 ISFI 的临床应用受到限制。本研究旨在使用扩散加权 MRI(DWI)非侵入性地定量原位植入物扩散率的时空变化。ISFI 由分子量分别为 15 kDa 和 52 kDa 的聚(乳酸-共-乙醇酸)和荧光素作为模拟药物形成。在 21 天内进行体外药物释放、聚合物侵蚀、聚合物降解和植入物扩散率分析。还在 5 天内进行了体内 DWI。使用 DWI 数据生成植入物的空间扩散率图。结果显示,植入物壳的扩散率保持不变((1.17±0.13)×10mm/s),而内部的扩散率随时间增加(从第 1 天的(0.268±0.081)×10mm/s 增加到第 14 天的(1.88±0.04)×10mm/s),这与植入物微观结构的孔隙率增加有关。体内形成的植入物与体外植入物具有相同的扩散趋势。这项研究验证了 DWI 的使用,通过其在体外和体内非侵入性地表征植入物内的传输特性的能力,为提供关于植入物行为的新功能信息提供了可能性。

相似文献

1
Noninvasive characterization of in situ forming implant diffusivity using diffusion-weighted MRI.使用扩散加权 MRI 无创表征原位形成植入物的扩散系数。
J Control Release. 2019 Sep 10;309:289-301. doi: 10.1016/j.jconrel.2019.07.019. Epub 2019 Jul 16.
2
Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.采用超声成像技术无创性分析不同 PLGA 分子量混合物对原位形成植入物行为的影响。
Theranostics. 2012;2(11):1064-77. doi: 10.7150/thno.4181. Epub 2012 Nov 8.
3
Effect of injection site on in situ implant formation and drug release in vivo.注射部位对体内原位植入物形成和药物释放的影响。
J Control Release. 2010 Nov 1;147(3):350-8. doi: 10.1016/j.jconrel.2010.08.020. Epub 2010 Aug 20.
4
Noninvasive characterization of in situ forming implants using diagnostic ultrasound.使用诊断超声对原位形成植入物进行无创特征描述。
J Control Release. 2010 Apr 19;143(2):183-90. doi: 10.1016/j.jconrel.2010.01.001. Epub 2010 Jan 11.
5
Initial Leuprolide Acetate Release from Poly(d,l-lactide--glycolide) Forming Implants as Studied by Ultraviolet-Visible Imaging.紫外可见成像研究聚(D,L-丙交酯-乙交酯)成型植入物中醋酸亮丙瑞林的初始释放。
Mol Pharm. 2020 Dec 7;17(12):4522-4532. doi: 10.1021/acs.molpharmaceut.0c00625. Epub 2020 Nov 9.
6
Effect of implant formation on drug release kinetics of in situ forming implants.植入物形成对原位形成植入物药物释放动力学的影响。
Int J Pharm. 2021 Jan 5;592:120105. doi: 10.1016/j.ijpharm.2020.120105. Epub 2020 Nov 21.
7
Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure.皮下环境对相敏原位成型植入物药物释放、降解及微观结构的影响
J Pharm Sci. 2015 Dec;104(12):4322-4328. doi: 10.1002/jps.24673. Epub 2015 Oct 27.
8
Implant dynamics, inner structure, and their impact on drug release of in situ forming implants uncovered through CT imaging.通过 CT 成像揭示原位形成植入物的植入物动力学、内部结构及其对药物释放的影响。
J Control Release. 2024 Nov;375:802-811. doi: 10.1016/j.jconrel.2024.09.045. Epub 2024 Oct 4.
9
Coloring of PLGA implants to better understand the underlying drug release mechanisms.聚乳酸-乙醇酸共聚物(PLGA)植入物的染色以更好地理解潜在的药物释放机制。
Int J Pharm. 2019 Oct 5;569:118563. doi: 10.1016/j.ijpharm.2019.118563. Epub 2019 Jul 24.
10
Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery.将二氧化硅颗粒掺入基于 PLGA 的原位形成植入物中利用了缓释和颗粒输送的双重优势。
Eur J Pharm Biopharm. 2020 Nov;156:1-10. doi: 10.1016/j.ejpb.2020.08.020. Epub 2020 Aug 27.

引用本文的文献

1
In vitro and in vivo evaluation of in situ forming polyester implants for the extended release of carvedilol.用于卡维地洛缓释的原位成型聚酯植入物的体外和体内评价
Drug Deliv Transl Res. 2025 May;15(5):1707-1718. doi: 10.1007/s13346-024-01706-7. Epub 2024 Sep 23.
2
An injectable magnesium-loaded hydrogel releases hydrogen to promote osteoporotic bone repair via ROS scavenging and immunomodulation.一种可注射的载镁水凝胶通过清除 ROS 和免疫调节释放氢气以促进骨质疏松性骨修复。
Theranostics. 2024 Jun 17;14(9):3739-3759. doi: 10.7150/thno.97412. eCollection 2024.
3
Mechanistic Computational Modeling of Implantable, Bioresorbable Drug Release Systems.植入式、可生物降解药物释放系统的机械计算建模。
Adv Mater. 2023 Dec;35(51):e2301698. doi: 10.1002/adma.202301698. Epub 2023 Sep 8.
4
Sustained degradation of hyaluronic acid using an in situ forming implant.使用原位成型植入物对透明质酸进行持续降解。
PNAS Nexus. 2022 Sep 17;1(4):pgac193. doi: 10.1093/pnasnexus/pgac193. eCollection 2022 Sep.
5
Basic Salt Additives Modulate the Acidic Microenvironment Around In Situ Forming Implants.基础盐添加剂调节原位形成植入物周围的酸性微环境。
Ann Biomed Eng. 2023 May;51(5):966-976. doi: 10.1007/s10439-022-03109-6. Epub 2022 Dec 1.
6
A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis.利福布汀长效制剂可有效预防和治疗结核分枝杆菌。
Nat Commun. 2022 Aug 8;13(1):4455. doi: 10.1038/s41467-022-32043-3.
7
Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics.注射体积和给药途径对多替拉韦原位形成植入剂药代动力学的影响。
Pharmaceutics. 2022 Mar 11;14(3):615. doi: 10.3390/pharmaceutics14030615.

本文引用的文献

1
Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.使用紫外可见成像技术,对原位形成的聚(丙交酯-乙交酯)酸植入物在模拟皮下组织的水凝胶基质中的植入物形成和药物释放进行同步监测。
J Pharm Biomed Anal. 2018 Feb 20;150:95-106. doi: 10.1016/j.jpba.2017.11.065. Epub 2017 Dec 2.
2
Clinical Intravoxel Incoherent Motion and Diffusion MR Imaging: Past, Present, and Future.临床体素内不相干运动和弥散磁共振成像:过去、现在和未来。
Radiology. 2016 Jan;278(1):13-32. doi: 10.1148/radiol.2015150244.
3
Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.用于肿瘤内药物输送的工程化原位形成储库水凝胶。
J Control Release. 2015 Dec 28;220(Pt A):465-475. doi: 10.1016/j.jconrel.2015.11.014. Epub 2015 Nov 14.
4
Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure.皮下环境对相敏原位成型植入物药物释放、降解及微观结构的影响
J Pharm Sci. 2015 Dec;104(12):4322-4328. doi: 10.1002/jps.24673. Epub 2015 Oct 27.
5
The Effect of Additives on the Behavior of Phase Sensitive In Situ Forming Implants.添加剂对相敏原位成型植入物性能的影响。
J Pharm Sci. 2015 Oct;104(10):3471-80. doi: 10.1002/jps.24558. Epub 2015 Jul 14.
6
Biomedical Imaging in Implantable Drug Delivery Systems.可植入药物递送系统中的生物医学成像
Curr Drug Targets. 2015;16(6):672-82. doi: 10.2174/1389450115666141122211920.
7
Controlled release for local delivery of drugs: barriers and models.用于药物局部递送的控释:障碍与模型
J Control Release. 2014 Sep 28;190:664-73. doi: 10.1016/j.jconrel.2014.04.048. Epub 2014 May 4.
8
An overview of clinical and commercial impact of drug delivery systems.药物递送系统的临床和商业影响概述。
J Control Release. 2014 Sep 28;190:15-28. doi: 10.1016/j.jconrel.2014.03.053. Epub 2014 Apr 18.
9
Solvent induced phase inversion-based in situ forming controlled release drug delivery implants.溶剂致相转化原位形成型控释药物传递植入物。
J Control Release. 2014 Feb 28;176:8-23. doi: 10.1016/j.jconrel.2013.12.020. Epub 2013 Dec 27.
10
PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release.聚乳酸-乙醇酸共聚物原位植入剂的相转化法制备:调控药物释放的关键理化参数。
J Control Release. 2013 Nov 28;172(1):292-304. doi: 10.1016/j.jconrel.2013.08.024. Epub 2013 Sep 1.